Janjigian, Y. Y. Et Al. 2024. Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results. JOURNAL OF CLINICAL ONCOLOGY , no.3_SUPPL , 286.

Janjigian, Y. Y., Kawazoe, A., Xu, J., Lonardi, S., Metges, J., Wyrwicz, L. S., ... Shen, L.(2024). Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results. JOURNAL OF CLINICAL ONCOLOGY , no.3_SUPPL, 286.

Janjigian, Yelena Et Al. "Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results," JOURNAL OF CLINICAL ONCOLOGY , no.3_SUPPL, 286, 2024

Janjigian, Yelena Y. Et Al. "Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results." JOURNAL OF CLINICAL ONCOLOGY , no.3_SUPPL, pp.286, 2024

Janjigian, Y. Y. Et Al. (2024) . "Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results." JOURNAL OF CLINICAL ONCOLOGY , no.3_SUPPL, p.286.

@article{article, author={Yelena Y. Janjigian Et Al. }, title={Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2024, pages={286} }